Theriva Biologics Stock Market Value
| TOVX Stock | USD 1.28 0.02 1.59% |
| Symbol | Theriva |
Theriva Biologics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theriva Biologics. If investors know Theriva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theriva Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (32.59) | Return On Assets (0.25) | Return On Equity (0.59) |
The market value of Theriva Biologics is measured differently than its book value, which is the value of Theriva that is recorded on the company's balance sheet. Investors also form their own opinion of Theriva Biologics' value that differs from its market value or its book value, called intrinsic value, which is Theriva Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theriva Biologics' market value can be influenced by many factors that don't directly affect Theriva Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theriva Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Theriva Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theriva Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Theriva Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Theriva Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Theriva Biologics.
| 11/30/2023 |
| 11/24/2024 |
If you would invest 0.00 in Theriva Biologics on November 30, 2023 and sell it all today you would earn a total of 0.00 from holding Theriva Biologics or generate 0.0% return on investment in Theriva Biologics over 360 days. Theriva Biologics is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need More
Theriva Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Theriva Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Theriva Biologics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 67.47 | |||
| Value At Risk | (24.57) | |||
| Potential Upside | 34.29 |
Theriva Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theriva Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Theriva Biologics' standard deviation. In reality, there are many statistical measures that can use Theriva Biologics historical prices to predict the future Theriva Biologics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (2.67) | |||
| Treynor Ratio | (0.37) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Theriva Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Theriva Biologics Backtested Returns
Theriva Biologics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0457, which indicates the firm had a -0.0457% return per unit of risk over the last 3 months. Theriva Biologics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Theriva Biologics' Coefficient Of Variation of (2,328), variance of 176.65, and Risk Adjusted Performance of (0.02) to confirm the risk estimate we provide. The entity has a beta of 1.56, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Theriva Biologics will likely underperform. At this point, Theriva Biologics has a negative expected return of -0.61%. Please make sure to validate Theriva Biologics' kurtosis, market facilitation index, and the relationship between the value at risk and rate of daily change , to decide if Theriva Biologics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.57 |
Modest predictability
Theriva Biologics has modest predictability. Overlapping area represents the amount of predictability between Theriva Biologics time series from 30th of November 2023 to 28th of May 2024 and 28th of May 2024 to 24th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Theriva Biologics price movement. The serial correlation of 0.57 indicates that roughly 57.0% of current Theriva Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.57 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 4.38 |
Theriva Biologics lagged returns against current returns
Autocorrelation, which is Theriva Biologics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Theriva Biologics' stock expected returns. We can calculate the autocorrelation of Theriva Biologics returns to help us make a trade decision. For example, suppose you find that Theriva Biologics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Theriva Biologics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Theriva Biologics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Theriva Biologics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Theriva Biologics stock over time.
Current vs Lagged Prices |
| Timeline |
Theriva Biologics Lagged Returns
When evaluating Theriva Biologics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Theriva Biologics stock have on its future price. Theriva Biologics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Theriva Biologics autocorrelation shows the relationship between Theriva Biologics stock current value and its past values and can show if there is a momentum factor associated with investing in Theriva Biologics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.